Cargando…
Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A monoclonal antibody over monalizumab for the treatment of cancer
A semimechanistic pharmacokinetic (PK)/receptor occupancy (RO) model was constructed to differentiate a next generation anti‐NKG2A monoclonal antibody (KSQ mAb) from monalizumab, an immune checkpoint inhibitor in multiple clinical trials for the treatment of solid tumors. A three‐compartment model i...
Autores principales: | Spinosa, Phillip, Musial‐Siwek, Monika, Presler, Marc, Betts, Alison, Rosentrater, Emily, Villali, Janice, Wille, Lucia, Zhao, Yang, McCaughtry, Tom, Subramanian, Kalyanasundaram, Liu, Hanlan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965834/ https://www.ncbi.nlm.nih.gov/pubmed/33501768 http://dx.doi.org/10.1002/psp4.12592 |
Ejemplares similares
-
Monalizumab: inhibiting the novel immune checkpoint NKG2A
por: van Hall, Thorbald, et al.
Publicado: (2019) -
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
por: Yaqinuddin, Ahmed, et al.
Publicado: (2020) -
Thymic emigration revisited
por: McCaughtry, Tom M., et al.
Publicado: (2007) -
Clonal deletion of thymocytes can occur in the cortex with no involvement of the medulla
por: McCaughtry, Tom M., et al.
Publicado: (2008) -
Competitive advantage
por: Anderson, Verl, et al.
Publicado: (2017)